APA (7th ed.) Citation

Lacout, C., Orvain, C., Seegers, V., De Vries, M., Mercier, M., Farhi, J., . . . Tanguy‐Schmidt, A. (2020). R‐DHA‐oxaliplatin (R‐DHAOx) versus R‐DHA‐cisplatin (R‐DHAP) regimen in B‐cell lymphoma treatment: A eight‐year trajectory study. European Journal of Haematology, 105(2), 223. https://doi.org/10.1111/ejh.13429

Chicago Style (17th ed.) Citation

Lacout, Carole, et al. "R‐DHA‐oxaliplatin (R‐DHAOx) Versus R‐DHA‐cisplatin (R‐DHAP) Regimen in B‐cell Lymphoma Treatment: A Eight‐year Trajectory Study." European Journal of Haematology 105, no. 2 (2020): 223. https://doi.org/10.1111/ejh.13429.

MLA (9th ed.) Citation

Lacout, Carole, et al. "R‐DHA‐oxaliplatin (R‐DHAOx) Versus R‐DHA‐cisplatin (R‐DHAP) Regimen in B‐cell Lymphoma Treatment: A Eight‐year Trajectory Study." European Journal of Haematology, vol. 105, no. 2, 2020, p. 223, https://doi.org/10.1111/ejh.13429.